表纸
市场调查报告书

鼠疫 : 开发平台分析

Plague - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 245959
出版日期 内容资讯 英文 64 Pages
订单完成后即时交付
价格
Back to Top
鼠疫 : 开发平台分析 Plague - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 64 Pages
简介

鼠疫是由于鼠疫这种细菌所引起的传染病。这个细菌主要寄生在老鼠身上的跳蚤上。人类及其他动物接触到老鼠及被跳蚤叮咬而感染。过去鼠疫曾经造成人类全体文明崩溃。现代由于生活水准的改善及抗生物质的进步,鼠疫终于成了一般疾病。鼠疫的一般症状出现在腹股沟及腋下、头部等腹股沟腺炎(淋巴结肿起、感到痛的所在)。鼠疫中罕见的严重情况,会侵袭肺部,并由人类互相传染。

本报告提供全球各国治疗鼠疫所用的开发中产品之开发情形相关分析,提供您开发中产品的最新趋势,及临床实验各阶段产品一览,主要企业简介,主要药物概要(产品概要,功能机制,研究开发(R&D)的发展情形),最新的产业趋势等调查,并将结果概述为以下内容。

简介

  • 分析范围

鼠疫概要

治疗药的开发

  • 鼠疫开发中产品:概要
  • 鼠疫开发中产品:比较分析

各企业开发中的鼠疫治疗药

大学/研究机关研究中的鼠疫治疗药

开发中产品的概要

  • 临床实验阶段的产品
  • 初期阶段的产品
  • 开发阶段不明的产品

鼠疫治疗药:开发中的产品一览(各企业)

鼠疫治疗药:研究中的产品一览(大学/研究机关别)

鼠疫开发治疗药的企业

  • Aradigm Corporation
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.

鼠疫:治疗药的评估

  • 单剂产品
  • 组合产品
  • 标的别
  • 各行动机制
  • 各投药法
  • 各分子类型
  • 各治疗分类

药物简介

  • 炭疽菌·鼠疫菌疫苗
  • ARD-3100
  • 鹽酸hydrochloride
  • 鼠疫菌疫苗
  • 肺血小板疫苗
  • 鼠疫蛋白质酪胺酸磷酸酶 (YopH) 抑制剂
  • TP-271
  • 鼠疫菌疫苗

鼠疫治疗药:最新的药物简介

鼠疫治疗药:暂停开发的产品

鼠疫治疗药:开发中止的产品

鼠疫相关产品的开发里程碑

  • 值得注意的最新趋势·新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11076IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2019, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plague - Overview
  • Plague - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Plague - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plague - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Aradigm Corp
    • Greffex Inc
    • iBio Inc
    • Prokarium Ltd
    • Tetraphase Pharmaceuticals Inc
  • Plague - Drug Profiles
    • (anthrax + plague) (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anthrax + plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GreAnPla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GrePla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISAS-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumonic plaque vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VypVaxDuo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2017: DynPorts clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation
      • Feb 14, 2013: BioDiem Extends Cooperative Agreement with USAMRIID
      • Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development
      • Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial
      • May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
      • Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Plague - Pipeline by Achaogen Inc, H1 2019
  • Plague - Pipeline by Aradigm Corp, H1 2019
  • Plague - Pipeline by Greffex Inc, H1 2019
  • Plague - Pipeline by iBio Inc, H1 2019
  • Plague - Pipeline by Prokarium Ltd, H1 2019
  • Plague - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Plague - Dormant Projects, H1 2019
  • Plague - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Plague, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top